Ahmed Ayesha, Al-Tamimi Dalal M
a Department of Pathology, College of Medicine , King Fahd Hospital of Imam Abdulrahman Bin Faisal University , Dammam , Saudi Arabia.
Libyan J Med. 2018 Dec;13(1):1466573. doi: 10.1080/19932820.2018.1466573.
Her2-neu overexpression has a pathogenetic, therapeutic and a controversial prognostic role in gastric cancer. p-53 mutation status and Ki-67 proliferation index are established prognostic markers in many tumors. In this study we evaluated p-53 and Ki-67 in relation to Her2-neu positive and negative gastric adenocarcinoma (GA). This cross-sectional study was carried out at King Fahd Hospital of Imam Abdulrahman bin Faisal University. Fifty cases of GA were retrieved from pathology archives. Clinico-pathological parameters were evaluated. Immunohistochemical protein analysis for Her2-neu, Ki-67 and p-53 was carried out. Fluorescent in situ hybridization (FISH) analysis was done for Her2-neu positive cases showing 2+ immunoexpression. Frequency of Ki-67 and p-53 positivity in Her2-neu positive cases was calculated and compared with those in Her2-neu negative cases. Correlation of clinicopatological parameters with Her2 positive and negative cases, p-53 mutation status and Ki-67 proliferation index was carried out. Her2-neu overexpression was present in 12% (n = 6) cases. A high Ki-67 was seen predominantly in Her2-neu positive cases (83%, n = 5). Her2-neu negative cases (n = 44) showed moderate (31.88%, n = 14) to low (34%, n = 15) Ki-67. Diffuse p-53 positivity was seen predominantly in Her2-neu positive cases (33.33%, n = 2). Focal p-53 was seen mainly in Her2-neu negative cases 56.8% (n = 25). Negative p-53 was seen to be independent of Her2-neu status. Her2-neu positivity is strongly associated with diffuse p-53 mutation status and high Ki-67 proliferation. Her 2-neu negative status is associated with focal p-53 positivity and low to moderate Ki-67 proliferation index. Such stratifications in prognostic markers could not only be predictive in patient's prognostics but could also form a basis of molecular classification of gastric cancer.
Her2-neu过表达在胃癌的发病机制、治疗及预后方面具有争议性作用。p-53突变状态和Ki-67增殖指数是许多肿瘤中已确立的预后标志物。在本研究中,我们评估了与Her2-neu阳性和阴性胃腺癌(GA)相关的p-53和Ki-67。这项横断面研究在伊玛目阿卜杜勒拉赫曼·本·费萨尔大学法赫德国王医院开展。从病理档案中检索出50例GA病例。评估临床病理参数。对Her2-neu、Ki-67和p-53进行免疫组织化学蛋白分析。对免疫表达为2+的Her2-neu阳性病例进行荧光原位杂交(FISH)分析。计算Her2-neu阳性病例中Ki-67和p-53阳性的频率,并与Her2-neu阴性病例进行比较。分析临床病理参数与Her2阳性和阴性病例、p-53突变状态及Ki-67增殖指数的相关性。12%(n = 6)的病例存在Her2-neu过表达。高Ki-67主要见于Her2-neu阳性病例(83%,n = 5)。Her2-neu阴性病例(n = 44)显示中度(31.88%,n = 14)至低度(34%,n = 15)的Ki-67。弥漫性p-53阳性主要见于Her2-neu阳性病例(33.33%,n = 2)。局灶性p-53主要见于Her2-neu阴性病例(56.8%,n = 25)。p-53阴性与Her2-neu状态无关。Her2-neu阳性与弥漫性p-53突变状态及高Ki-67增殖密切相关。Her2-neu阴性状态与局灶性p-53阳性及低至中度Ki-67增殖指数相关。这种预后标志物的分层不仅可以预测患者的预后,还可以形成胃癌分子分类的基础。